Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AADI

AADI - Aadi Bioscience, Inc. Stock Price, Fair Value and News

1.43USD-0.10 (-6.54%)Market Closed

Market Summary

AADI
USD1.43-0.10
Market Closed
-6.54%

AADI Stock Price

View Fullscreen

AADI RSI Chart

AADI Valuation

Market Cap

35.1M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

1.47

EV/EBITDA

0.24

Price/Free Cashflow

-0.57

AADI Price/Sales (Trailing)

AADI Profitability

EBT Margin

-270.40%

Return on Equity

-76.09%

Return on Assets

-61.97%

Free Cashflow Yield

-174.72%

AADI Fundamentals

AADI Revenue

Revenue (TTM)

23.8M

Rev. Growth (Yr)

-8.76%

Rev. Growth (Qtr)

-15.38%

AADI Earnings

Earnings (TTM)

-68.8M

Earnings Growth (Yr)

-20.14%

Earnings Growth (Qtr)

-12.42%

Breaking Down AADI Revenue

Last 7 days

-7.7%

Last 30 days

-11.2%

Last 90 days

-22.3%

Trailing 12 Months

-75.6%

How does AADI drawdown profile look like?

AADI Financial Health

Current Ratio

5.16

AADI Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

-2.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202423.8M000
202318.8M21.5M23.3M24.4M
202214.3M14.6M14.9M15.2M
202114.0M14.0M14.0M14.0M
202018.6M17.1M15.5M14.0M
201806.8M13.5M20.2M
2017158.3K88.6K108.8K93.7K
2016310.1K250.5K190.9K131.3K
2015000369.7K

Tracking the Latest Insider Buys and Sells of Aadi Bioscience, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 02, 2024
desai neil
sold
-11,611
1.3421
-8,652
executive chairman
Jul 01, 2024
desai neil
sold
-45,605
1.4548
-31,348
executive chairman
Jun 04, 2024
desai neil
sold
-35,745
1.7674
-20,225
executive chairman
Jun 03, 2024
desai neil
sold
-35,765
1.8086
-19,775
executive chairman
May 01, 2024
desai neil
sold
-77,184
1.9296
-40,000
executive chairman
Apr 02, 2024
desai neil
sold
-49,512
2.2275
-22,228
executive chairman
Apr 01, 2024
desai neil
sold
-41,101
2.3127
-17,772
executive chairman
Mar 04, 2024
desai neil
sold
-31,415
2.0994
-14,964
executive chairman
Mar 01, 2024
desai neil
sold
-53,225
1.9687
-27,036
executive chairman
Feb 01, 2024
desai neil
sold
-73,269
1.7445
-42,000
executive chairman

1–10 of 48

Which funds bought or sold AADI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
1,210
168
191
-%
Jul 12, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
unchanged
-
-1,173
1,946
-%
Jul 10, 2024
CWM, LLC
added
544
-
-
-%
Jul 01, 2024
Legal & General Group Plc
unchanged
-
475
3,473
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-31.01
-1,083
4,310
-%
May 15, 2024
683 Capital Management, LLC
unchanged
-
64,000
468,000
0.03%
May 15, 2024
Lion Point Capital, LP
sold off
-100
-166,494
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-33.62
-2,461
8,187
-%
May 15, 2024
ACUTA CAPITAL PARTNERS, LLC
unchanged
-
591,809
4,327,600
2.81%
May 15, 2024
Engineers Gate Manager LP
sold off
-100
-23,133
-
-%

1–10 of 48

Are Funds Buying or Selling AADI?

Are funds buying AADI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AADI
No. of Funds

Unveiling Aadi Bioscience, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
vivo panda, llc
2.1%
509,572
SC 13G/A
Feb 10, 2023
satter muneer a
6.7%
1,630,830
SC 13G/A
Jan 17, 2023
desai neil
10.8%
2,635,196
SC 13D/A
Oct 04, 2022
satter muneer a
5.3%
1,294,785
SC 13G
Sep 26, 2022
avoro capital advisors llc
11.7%
2,849,402
SC 13D/A
Feb 14, 2022
biotechnology value fund l p
2.2%
465,262
SC 13G/A
Feb 14, 2022
venrock healthcare capital partners ii, l.p.
7.3%
1,529,402
SC 13G
Feb 11, 2022
vivo panda, llc
2.8%
575,723
SC 13G/A
Feb 09, 2022
vanguard group inc
3.64%
761,473
SC 13G/A

Recent SEC filings of Aadi Bioscience, Inc.

View All Filings
Date Filed Form Type Document
Jul 02, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 12, 2024
8-K
Current Report
Jun 05, 2024
4
Insider Trading

Peers (Alternatives to Aadi Bioscience, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Aadi Bioscience, Inc. News

Latest updates
The Dales Report15 Jul 202411:01 am

Aadi Bioscience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12018Q42018Q32018Q2
Revenue-15.4%5,353,0006,326,0005,959,0006,202,0005,867,0005,227,0004,245,0003,437,0002,307,000-------15,000,0007,501,0722,14418,821,9531,333,333
Costs and Expenses3.4%24,865,00024,040,00023,808,00025,747,00022,692,00020,698,50019,281,00021,797,00016,121,00016,944,500-87,311,0003,875,0004,207,000-------
Operating Expenses----------15,798,388-87,311,0004,771,3615,602,8635,060,4902,894,0005,744,0874,114,9338,868,3227,623,9167,369,788
  S&GA Expenses2.7%10,620,00010,345,00011,221,00011,776,00011,207,00011,107,0009,915,00010,006,0009,148,0009,717,500-7,401,000830,000563,000-1,219,203499,0002,195,5152,285,8913,619,6923,277,5353,140,854
  R&D Expenses6.5%13,593,00012,768,00011,890,00013,315,00010,956,0009,369,5008,773,0007,726,0006,794,0007,227,000-5,754,0003,045,0003,644,0006,279,6932,395,0003,548,5721,829,0425,248,6304,346,3814,228,934
EBITDA Margin-2.1%-2.69-2.63-2.68-2.98-3.20-3.95-4.17-9.22-8.23-7.81-0.19-0.19-0.18--------
Interest Expenses1.8%58,00057,00058,00058,00058,00056,50058,00058,00058,00057,000-157,000227,000224,000230,000229,000-----
Income Taxes-------9,000-9,000----2,000--1,000-----
Earnings Before Taxes100.0%--16,269,000-16,302,000-17,971,000--13,922,000-14,474,000-18,260,000-13,857,000-15,990,000--87,088,000-1,534,000-5,476,000--2,891,000-----
EBT Margin-2.2%-2.70-2.65-2.69-3.00-3.22-3.98-4.20-9.25-8.28-7.86-0.25-0.25-0.25--------
Net Income-12.4%-18,289,000-16,269,000-16,302,000-17,971,000-15,223,000-13,913,000-14,474,000-18,269,000-13,857,000-15,990,000--87,088,000-1,536,000-5,476,0008,020,000-2,892,000-5,282,000-3,324,000-8,518,59011,537,478-5,989,992
Net Income Margin-6.9%-2.89-2.70-2.73-2.86-3.30-3.98-4.20-9.26-8.28-7.86-6.15-6.15-0.13--------
Free Cashflow-95.0%-20,392,000-10,460,000-13,049,000-17,447,000-22,679,000-11,388,000-8,297,000-10,961,000-19,438,000-12,474,000-17,373,000-17,373,000-3,185,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-16.1%11113214015117118419412914215816937.0041.0019.0050.0046.0036.0040.0046.0050.0055.00
  Current Assets-17.7%10312513314516518019012413615116237.0041.0019.0050.0045.0035.0040.0045.0049.0054.00
    Cash Equivalents-14.5%54.0063.0069.0068.0034.0039.0013511913014916137.0039.004.0047.0045.0035.0039.0043.0048.0053.00
  Inventory-7.6%6.006.004.003.004.002.001.001.000.00------------
  Net PPE18.4%6.005.004.003.002.001.000.000.000.000.000.00-0.000.000.000.000.000.000.000.000.00
Liabilities-24.3%21.0027.0021.0020.0025.0026.0025.0020.0018.0022.0018.002.002.0031.003.003.003.003.004.004.004.00
  Current Liabilities-24.7%20.0026.0021.0013.0018.0019.0018.0013.0012.0015.0012.002.002.0030.003.003.003.003.004.004.004.00
Shareholder's Equity-14.0%90.0010511813114615816910912513615135.0039.0043.0047.0043.0033.0037.0042.0046.0051.00
  Retained Earnings-6.8%-287-268-252-236-218-203-189-174-156-142-126-155-150-32.59-141-136-146-142-137-133-127
  Additional Paid-In Capital1.0%37837437136836436235828428127927819119020.00189179179179179179178
Shares Outstanding0%25.0025.0025.0025.0027.0024.0021.0021.0021.0021.0010.003.00---------
Float----111---178---60.00---49.00---26.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-103.8%-19,653-9,644-11,951-16,758-21,310-11,310-8,195-10,720-19,415-12,428-17,373-3,18510,563-3,275-15,77710,292-3,939-4,865-4,763-5,146-9,078
  Share Based Compensation15.4%3,5893,1113,0493,0542,7402,8702,7572,2351,7811,38364839.0036.00-24534.00308327-786646605622
Cashflow From Investing189.3%10,5553,64912,66750,56116,329-84,379-48,243-241-23.00-46.0025,356----6.83--1*-4.28-119-113
Cashflow From Financing-112.5%-10.0080.00-75.003138.00-10772,516-87.0029888.00141,717-71.2870.00--------
  Dividend Payments----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AADI Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 5,353$ 5,867
Operating expenses  
Selling, general and administrative10,62011,207
Research and development13,59310,956
Cost of goods sold652529
Total operating expenses24,86522,692
Loss from operations(19,512)(16,825)
Other income (expense)  
Foreign exchange loss(1)0
Interest income1,2821,660
Interest expense(58)(58)
Total other income (expense), net1,2231,602
Net loss(18,289)(15,223)
Other comprehensive (loss) income:  
Unrealized (loss) income on available-for-sale debt securities(35)83
Comprehensive loss$ (18,324)$ (15,140)
Net loss per share, basic (in dollars per share)$ (0.68)$ (0.57)
Net loss per share, diluted (in dollars per share)$ (0.68)$ (0.57)
Weighted average number of common shares outstanding, basic (in shares)26,980,69826,862,646
Weighted average number of common shares outstanding, diluted (in shares)26,980,69826,862,646
Product sales, net  
Total revenue$ 5,353$ 5,867

AADI Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 53,780$ 62,888
Short-term investments34,49145,957
Accounts receivable, net4,9335,488
Inventory5,9366,427
Prepaid expenses and other current assets3,4333,826
Total current assets102,573124,586
Property and equipment, net5,6864,802
Operating lease right-of-use assets1,0771,169
Other assets1,7371,866
Total assets111,073132,423
Current liabilities:  
Accounts payable3,0955,898
Accrued liabilities10,59814,306
Operating lease liabilities, current portion425434
Due to licensor payable (Note 7)5,7575,757
Total current liabilities19,87526,395
Operating lease liabilities, net of current portion738833
Total liabilities20,61327,228
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 300,000,000 shares authorized; 24,554,205 shares issued and outstanding as of March 31, 2024 and December 31, 202322
Additional paid-in capital377,718374,129
Accumulated other comprehensive (loss) income(8)27
Accumulated deficit(287,252)(268,963)
Total stockholders’ equity90,460105,195
Total liabilities and stockholders’ equity$ 111,073$ 132,423
Common stock, shares issued (in shares)24,554,20524,554,205
Common stock, shares outstanding (in shares)24,554,20524,554,205
AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
 CEO
 WEBSITEhttps://aadibio.com
 INDUSTRYBiotechnology
 EMPLOYEES89

Aadi Bioscience, Inc. Frequently Asked Questions


What is the ticker symbol for Aadi Bioscience, Inc.? What does AADI stand for in stocks?

AADI is the stock ticker symbol of Aadi Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aadi Bioscience, Inc. (AADI)?

As of Fri Jul 19 2024, market cap of Aadi Bioscience, Inc. is 35.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers. The fair value of Aadi Bioscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aadi Bioscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AADI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aadi Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether AADI is over valued or under valued. Whether Aadi Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Aadi Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AADI.

What is Aadi Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AADI's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 1.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AADI PE ratio will change depending on the future growth rate expectations of investors.